within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G01A_AntiinfectivesAndAntisepticsExclCombinationsWithCorticosteroids.G01AF06_Ornidazole;

model Ornidazole
  extends Pharmacolibrary.Drugs.ATC.G.G01AF06;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>G01AF06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ornidazole is a nitroimidazole antimicrobial agent used primarily for the treatment of protozoal infections and anaerobic bacterial infections. It is structurally related to metronidazole and is active against Giardia lamblia, Entamoeba histolytica, and Trichomonas vaginalis, as well as various anaerobic bacteria. Ornidazole is approved for clinical use in several countries, though not in all regions worldwide.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after a single oral dose.</p><h4>References</h4><ol><li><p>Cao, Y, et al., &amp; Wu, H (2023). Population pharmacokinetics of levornidazole in healthy subjects and patients, and sequential dosing regimen proposal using pharmacokinetic/pharmacodynamic analysis. <i>International journal of antimicrobial agents</i> 61(4) 106754â€“None. DOI:<a href=\"https://doi.org/10.1016/j.ijantimicag.2023.106754\">10.1016/j.ijantimicag.2023.106754</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36773938/\">https://pubmed.ncbi.nlm.nih.gov/36773938</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Ornidazole;
